Results from an early phase clinical trial presented this week at the World Conference on Lung Cancer Meeting in Barcelona, Spain, and published in the Nature Medicine journal today [Monday, 8th September 2025] show that patients with mesothelioma – a rare cancer of the lining of the lung that may be caused by exposure to asbestos – who received a combination of two immunotherapy drugs, nivolumab and ipilimumab, before surgery had successful surgeries and encouraging early outcomes.